EyePoint advances with Duravyu Phase III trial
EyePoint has entered the final phase of development for its lead product, Duravyu, announcing the completion of patient enrolment for…
Analyst Comment
Solid tumours: CAR-T therapies’ Waterloo
Genentech to onshore US manufacturing amid rising drug pricing tensions
UK biopharma innovator venture financing surges to $1.1bn in Q1 2025
ATS 2025: Real-world cohort study aligns with GSK depemokimab narrative
ATS 2025: GSK strengthens argument for twice-annual depemokimab
China’s mAb and ADC licensing was 3xUS’s in 2024 — will trade tensions slow it?
ATS 2025: Sanofi and Regeneron to launch new AIM4 trial for personalised asthma care
